9,37 €
2,55 %heute
L&S, 28. Februar, 08:17 Uhr
ISIN
US67576A1007
Symbol
OCUL
Berichte
Sektor
Industrie

Ocular Therapeutix Inc Aktie News

Positiv
InvestorPlace
3 Tage alt
While people tend to avoid price hikes, certain stocks up 100% this year just might provide an exception to the rule. Basically, not even two months have passed by.
Neutral
GlobeNewsWire
6 Tage alt
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has granted inducement equity awards to its newly appointed Executive Chair...
Neutral
GlobeNewsWire
6 Tage alt
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered into a securities purchase agreement with a select group o...
Neutral
GlobeNewsWire
6 Tage alt
Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S.
Positiv
Seeking Alpha
8 Tage alt
Ocular Therapeutix and Fat Brands have solid growth and momentum in SA Quant Factor Grades with potentially high upside in line with consensus price targets. Ocular Therapeutix is up over 50% in the past 30 days and has 15%+ sales growth YoY. The stock has almost 80% upside potential according to sell-side analyst targets. Fat Brands is up 20% in the past year, with forward EBIT growth at ~260%...
Neutral
PRNewsWire
9 Tage alt
SHANGHAI , Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health Sciences Authority (HSA) has accepted its New Drug Application (NDA) for DEXTENZA® (0.4 mg dexameth...
Neutral
GlobeNewsWire
13 Tage alt
Strategic promotion underscores commitment to commercial growth across Ocular portfolio Strategic promotion underscores commitment to commercial growth across Ocular portfolio
Neutral
GlobeNewsWire
15 Tage alt
Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD Phase 3 SOL-1 study will evaluate the efficacy and safety of AXPAXLI in wet AMD

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen